4 rapid COVID-19 test recalls announced by FDA this week

The FDA recently posted recall notices for four rapid COVID-19 tests recalled since Jan. 13.

Advertisement

The recalls were classified as class I recalls, the most serious type.

Here are the four recalls, starting with the most recent: 

1. Celltrion USA recalled 45,500 units of its DiaTrust COVID-19 Ag Rapid Tests on Feb. 28 due to high numbers of false positive reports.

2. SD Biosensor recalled up to 397,000 units of the Standard Q COVID-19 Ag Home Test on Jan. 31. The test is not authorized, cleared, or approved by the FDA for marketing or distribution in the U.S.  

3. E25Bio recalled 73,300 units of its COVID-19 Direct Antigen Rapid Test on Jan. 27. The test is not authorized, cleared, or approved by the FDA for marketing or distribution in the U.S.  

4. LuSys Laboratories recalled 164,250 units of its COVID-19 antigen tests on Jan. 13 due to lack of emergency use authorization. The manufacturer also did not provide appropriate validation data to show that the tests can perform accurately. 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.